Guardian Pharmacy Services, Inc.
GRDNNYSE
$40.52
↑ +0.4%Jul 17 close · end-of-day
Price
1Y↑ +95.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.5B
Net Income (TTM)
$53.1M
Free Cash Flow (TTM)
—
Gross Margin
20.9%
Operating Margin
5.3%
Net Margin
3.6%
ROE
22.8%
ROIC
31.3%
Debt / Equity
—
Net Cash
$64.9M
Return 1Y
+94.7%
Company profile
We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of long-term health care facilities (“LTCFs”) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. Our principal executive offices are located at 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia.
- CEO
- Fred P. Burke
- Sector
- Retail Trade
- Industry
- Retail
- Headquarters
- Georgia
- Website
- guardianpharmacy.com
Management & directors
- Burke FredSee Remarks
- Forbes KendallSee Remarks
- Morris David KSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
GRDN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$336.6M↑ +2.2%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $1.2B | $1.4B |
| Gross profit | $244.4M | $292.7M |
| Operating income | -$62.9M | $72.7M |
| Net income | -$110.0M | $49.2M |
| Diluted EPS | — | — |
| Operating cash flow | $58.0M | $100.3M |
| Free cash flow | — | — |
| Gross margin | 19.9% | 20.2% |
| Operating margin | -5.1% | 5.0% |
| Net margin | -9.0% | 3.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300.0M | $314.4M | $338.6M | $329.3M | $344.3M | $377.4M | $397.6M | $336.6M |
| Gross profit | $61.3M | $60.9M | $67.1M | $64.3M | $68.1M | $74.7M | $85.5M | $76.3M |
| Operating income | $17.0M | -$104.6M | $16.8M | $13.0M | $12.6M | $16.4M | $30.8M | $17.7M |
| Net income | $0.00 | -$122.0M | — | $9.4M | $9.0M | $9.8M | $20.9M | $13.3M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | $29.1M | -$2.2M | $22.3M | $17.6M | $19.9M | $28.2M | $34.6M | $6.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 20.4% | 19.4% | 19.8% | 19.5% | 19.8% | 19.8% | 21.5% | 22.7% |
| Operating margin | 5.7% | -33.3% | 4.9% | 3.9% | 3.7% | 4.3% | 7.7% | 5.3% |
| Net margin | 0.0% | -38.8% | — | 2.9% | 2.6% | 2.6% | 5.3% | 3.9% |
Company news
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-05 | COSLER STEVEN D | Award | 4,028 | $0.00 | $0.00 | filing |
| 2026-05-05 | LEWIS RANDALL J | Award | 4,028 | $0.00 | $0.00 | filing |
| 2026-05-05 | Patchett Mary Sue | Award | 4,028 | $0.00 | $0.00 | filing |
| 2026-03-28 | Pharmacy Investors, LLC | Option exercise | 1,413,939 | — | — | filing |
| 2026-03-28 | BINDLEY WILLIAM E | Option exercise | 6,100,175 | — | — | filing |
| 2026-03-28 | Forbes Kendall· See Remarks | Option exercise | 608,570 | — | — | filing |
| 2026-03-28 | Morris David K· See Remarks | Option exercise | 641,869 | — | — | filing |
| 2026-03-28 | Cardinal Equity Fund, L.P. | Option exercise | 471,057 | — | — | filing |
| 2026-03-28 | Bindley Capital Partners I, LLC | Option exercise | 6,100,175 | — | — | filing |
| 2026-03-28 | Ackerman John | Option exercise | 1,413,939 | — | — | filing |
| 2026-03-28 | Ackerman John | Option exercise | 471,057 | — | — | filing |
| 2026-03-28 | Salentine Thomas J Jr | Option exercise | 6,100,175 | — | — | filing |
| 2026-03-28 | Burke Fred· See Remarks | Option exercise | 1,298,826 | — | — | filing |
| 2026-03-20 | Bindley Capital Partners I, LLC | Sale | 3,570,677 | $29.68 | $106.0M | filing |
| 2026-03-20 | BINDLEY WILLIAM E | Sale | 3,570,677 | $29.68 | $106.0M | filing |
| 2026-03-20 | Salentine Thomas J Jr | Sale | 3,570,677 | $29.68 | $106.0M | filing |
| 2026-03-20 | Pharmacy Investors, LLC | Sale | 827,636 | $29.68 | $24.6M | filing |
| 2026-03-20 | Ackerman John | Sale | 827,636 | $29.68 | $24.6M | filing |
| 2026-03-20 | Burke Fred· See Remarks | Sale | 671,432 | $29.68 | $19.9M | filing |
| 2026-03-20 | Forbes Kendall· See Remarks | Sale | 346,672 | $29.68 | $10.3M | filing |
| 2026-03-20 | Cardinal Equity Fund, L.P. | Sale | 275,728 | $29.68 | $8.2M | filing |
| 2026-03-20 | Ackerman John | Sale | 275,728 | $29.68 | $8.2M | filing |
| 2026-03-20 | Morris David K· See Remarks | Sale | 187,855 | $29.68 | $5.6M | filing |
| 2026-03-01 | Forbes Kendall· See Remarks | Award | 8,952 | $0.00 | $0.00 | filing |
| 2026-03-01 | Morris David K· See Remarks | Award | 8,952 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.